布洛芬对阿司匹林心脏保护作用的影响
1Medicines Monitoring Unit, Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, DD1 9SY, Dundee, UK. t.m.macdonald@dundee.ac.uk
Lancet (London, England)
|February 25, 2003
概括
将布洛芬与低剂量阿司匹林结合使用可能会增加患有心血管疾病的患者心血管死亡风险. 这种组合疗法可能会抵消阿司匹林的作用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 低剂量阿司匹林广泛用于心血管疾病患者的心脏保护.
- 非类固醇抗炎药物,如布洛芬,通常用于缓解疼痛.
- 阿司匹林和布洛芬之间的潜在相互作用可能会影响心血管结果.
研究的目的:
- 为了研究患有已确定的心血管疾病的患者服用低剂量阿司匹林和布洛芬的心血管死亡风险.
- 评估与阿司匹林同时使用布洛芬是否会影响阿司匹林的心脏保护益处.
主要方法:
- 一项对7107名心血管疾病患者的队列研究,这些患者在首次入院后就医出院.
- 患者被处方低剂量阿司匹林 (<325毫克/天),并在出院后至少存活了一个月.
- 单独使用阿司匹林与阿司匹林加布罗芬的患者之间死亡风险的比较.
主要成果:
- 服用阿司匹林加上易布洛芬的患者显示所有原因死亡风险增加 (调整后危险比1.93).
- 在阿司匹林加上布洛芬组 (调整后危险比1.73) 观察到心血管死亡风险显著增加.
- 这些发现表明,易布洛芬和阿司匹林的心脏保护作用之间可能存在相互作用.
结论:
- 同时使用布洛芬和低剂量阿司匹林与已确定的心血管疾病患者的死亡率增加有关.
- 布洛芬可能会干扰阿司匹林的心脏保护机制.
- 临床医生在为心血管保护而接受低剂量阿司匹林治疗的患者开布洛芬时应谨慎行事.
相关概念视频
Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Drug Binding to Blood Components
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
Factors Affecting Protein-Drug Binding: Protein-Related Factors
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
Factors Affecting Protein-Drug Binding: Drug Interactions
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...


